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Summary 
 
The antihyperlipidemic activity of Spirulina platensis (family: 
Oscillatoriacae, cynobacteria/blue green algae) was evaluated 
in isoproterenol-induced hyperlipidemic rats. In the present 
study, Spirulina platensis powder suspended in water was 
administered orally to rats for 21 days at the dose of 450 
mg/kg/day followed by subcutaneous administration of 
isoproterenol (200 mg/kg/day for 2 days). Isoproterenol, a 
synthetic catecholamine and β-adrenergic agonist has reported 
to cause oxidative stress with subsequent increase in serum 
lipid profile after subcutaneous administration. 
The clinical biochemistry parameters like serum cholesterol, 
triglycerides, HDL-cholesterol, atherogenic index, VLDL and 
LDL cholesterol of the rats were determined for the evaluation 
of antihyperlipidemic activity of Spirulina platensis. The 
minimum alteration in clinical biochemistry parameters were 
observed in Spirulina platensis treated animals as compared to 
control animals indicating its antihyperlipidemic potential. 
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Cardiovascular disorder has become the leading cause of death worldwide. 
Epidemiological studies established a direct relationship of serum cholesterol and 
coronary artery disease [1]. Hyperlipidemia is characterized by increased triglyceride-rich 
lipoproteins, postprandial lipemia and decreased high-density lipoprotein (HDL) 
cholesterol [2]. The efforts of lowering lipid levels in different studies indicated lower 
morbidity and mortality in coronary heart disease which commensurate with reduction of 
serum cholesterol [3]. 
 
Spirulina platensis (family: Oscillatoriacae) is a blue green algae comprising of vital 
nutrients such as proteins, lipids and carbohydrates. It also contains essential elements 
like Zinc, Magnesium, Manganese, Selenium, and some vitamins like β–carotene, 
riboflavin, cyanocobalamine, α-tocopherol and α–linoleic acid. All these minerals, 
nutrients and vitamins promote physical health, improve the non specific resistance of the 
body, prevent the disturbances in homeostasis of the human system and promote revival 
of physiological functions after debilitating diseases. It also exhibits antioxidant activity 
[4, 5]. 
 
Isoproterenol, a synthetic catecholamine and β-adrenergic agonist has reported to cause 
oxidative stress in the myocardium, resulting in infarct-like necrosis of heart muscle [6]. 
The pathophysiological changes following isoproterenol administration were compared to 
human myocardial infarction [7]. 
 
Mathew et al, reported an altered lipid metabolism in myocardial necrosis following 
isoproterenol administration [8]. The present study investigated the beneficial effect of 
Spirulina platensis pretreatment in isoproterenol-induced hyperlipidemia in rats. 
 
Methods 
 
Plant product 
Spirulina platensis was received as a gift sample in the form of spray dried powder from 
M/s Parry Nutraceuticals, Ltd., Chennai, Tamilnadu, India. It has also other constituents 
like pigments, vitamins and minerals. 
 
The composition of the spray dried green powder of Spirulina platensis (Constituent/100 
g) was as follows: 
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Major constituents 
Proteins: 60-69% Fats: 6.7% 
Crude fibres: 9.3% Carbohydrates: 16% 
Vitamins 
Beta carotene: 3,20,000 I.U. Biotin: 0.22 mg 
Cynocobalamine: 65.7 mg Folic acid: 17.6 mg 
Inositol: 0.018 mg Niacin: 6.69 mg 
Pyridoxin HCl: 0.39 mg Riboflavin: 1.78 mg 
Thiamine: 0.118 mg Tocoferol (E): 0.733 I.U. 
Minerals 
Calcium: 131.5 mg Iron: 58 mg 
Sodium: 41.2 mg Chloride: 440 mg 
Magnesium: 191 mg Zinc: 3.9 mg 
Potassium: 1540 mg  
 
Animals 
Wistar albino rats of either sex (180-220 g) randomly bred in the registered animal house 
facility of M.U.I.C.T., Mumbai, India were used for the study. The animals were housed 
in standard environmental conditions of temperature (22±5 0C) and humidity (55±15 %) 
with 12-h light-dark cycles. They were fed with commercial pelleted feed (M/s D. S. 
Trading Co., Mumbai) and water ad libitum. All the procedures were performed in 
accordance with the Institutional Animal Ethics Committee (IAEC) constituted as per the 
directions of the Committee for the Purpose of Control and Supervision of Experiments 
on Animals (CPCSEA) under Ministry of Animal Welfare Division, Government of India, 
New Delhi, India [9]. The Institutional Animal Ethics Committee of M.U.I.C.T., 
Department of Pharmaceutical Sciences, approved the experimental protocol. 
 
Experimental Design 
The rats were divided into two groups of 12 animals each. Group 1 was treated as a 
control and received purified water (10 ml/kg/day for 21 days) by oral route. Group 2 
received suspension of Spirulina platensis powder in water at the dose of 450 mg/kg/day, 
orally for a period of 21 days. At the end of 21 days, the rats from group 1 were divided 
in subgroups I and II and animals of group 2 were divided in subgroups III and IV. The 
treatments received in different groups were as follows. 
I) Control group II) Control with Isoproterenol (200 mg/kg, s.c.), III) Spirulina platensis 
(450 mg/kg) and IV) Spirulina platensis (450 mg/kg) with isoproterenol (200 mg/kg, s.c.) 
 
Induction of Hyperlipidemia 
To induce hyperlipedemia, animals from group II and IV received Isoproterenol  (Sigma, 
USA, 200 mg/kg, s.c.) twice at an interval of 24 hours [10].  
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Blood Collection 
After the experimental period (i.e. 24 hour after second administration of isoproterenol) 
the blood was collected through retro-orbital plexus under light ether anesthesia in the 
eppendorf tubes. The serum was separated by spinning in temperature-controlled 
centrifuge (Superspin R-V/FM, Plasto Crafts, India). The serum from group I and III were 
also separated similarly.  
 
Serum Lipid profile 
The serum cholesterol, triglycerides and HDL cholesterol were estimated in serum by 
using kits procured from Merck Ecoline®, Mumbai, India. The serum total lipids were 
determined by using commercially available kit manufactured by Span Diagnostics Ltd., 
Sachin, Surat, India. The LDL cholesterol and VLDL were calculated using Friedwalds 
formula [11] and method of Godkar [12]. 
VLDL = Triglyerides/5 
LDL cholesterol = Cholesterol – (HDL Cholesterol + VLDL/5) 
 
Statistical analysis 
The data were expressed as the mean ± S.E.M. obtained from the number of experiments 
(n=6). One-way ANOVA with Tukey’s test was performed using GraphPad Prism 
version 4.00 for Windows, GraphPad Software [13], San Diego California USA, 
www.graphpad.com. The statistical significance was accepted at p<0.05. 
 
Results 
 
Effect of Spirulina platensis on cholesterol, triglycerides and total lipids 
The serum concentration of cholesterol, triglycerides and total lipids was decreased 
significantly (P<0.01) in Spirulina platensis pretreated (21 days) groups as presented in 
table 1 compared to isoproterenol treated control. 
Table 1 Effect of Spirulina platensis pretreatment (450 mg/kg, p.o.) on cholesterol, 
triglycerides and total lipids. 
Groups Treatment Cholesterol (mg/dl) 
Triglycerides 
(mg/dl) 
Total Lipids 
(mg/dl) 
I Control 103.4±6.26 65.8±4.91 451.8±14.38 
II Isoproterenol control (200 mg/kg s.c.) 135.0±4.63 114.1±5.43 485.6±13.85 
III S. platensis (450 mg/kg, p.o.) 104.5±6.32 a 61.3±4.87 b 452.0±14.32 
IV S. platensis (450 mg/kg, p.o.) + isoproterenol (200 mg/kg, s.c.) 109.4±5.21
 a 82.2±5.16 a 455.6±13.37 b 
Values are expressed as mean ± S.E.M. from 6 animals. Statistical analysis by one-way 
ANOVA followed by Tukey’s test using Graphpad Prism software; aP < 0.01 and bP 
<0.05 compared to isoproterenol control (200 mg/kg, s.c.). 
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Effect of Spirulina platensis on LDL and HDL cholesterol and LDLc/HDLc risk 
factor 
The serum concentration of LDL cholesterol was elevated due to isoproterenol 
administration in group II but it was not increased in III and IV as the Spirulina platensis 
pretreated group. HDL cholesterol was also increased significantly (P<0.01) in Spirulina 
platensis treated groups compared to isoproterenol control. The increase in HDL 
cholesterol and decrease in LDL cholesterol results in reduction of cardiovascular risk 
factor LDLc/HDLc in Spirulina platensis treated group compared to isoproterenol 
control. The results are mentioned in table 2. 
Table 2 Effect of Spirulina platensis pretreatment (450 mg/kg, p.o.) on HDL cholesterol, 
LDL cholesterol, and LDLc/HDLc risk factor. 
Groups Treatment 
HDL 
cholesterol 
(mg/dl) 
LDL 
cholesterol 
(mg/dl) 
Risk factor 
LDLc/HDLc
I Control 20.6±1.45 34.6±1.45 1.7±0.19 
II Isoproterenol control (200 mg/kg s.c.) 14.2±1.46 36.4±1.69 2.6±0.26 
III S. platensis (450 mg/kg) 22.2 ±1.23 a 44.2 ±1.25 a 2.0±0.13 
IV S. platensis (450 mg/kg) + isoproterenol (200 mg/kg, s.c.) 21.5±1.38
 a 35.1±1.55 b 1.6±0.15 b 
Values are expressed as mean ± S.E.M. from 6 animals. Statistical analysis by one-way 
ANOVA followed by Tukey’s test using Graphpad Prism software; aP < 0.01 and bP 
<0.05 compared to isoproterenol control (200 mg/kg, s.c.). 
 
Effect of Spirulina platensis on atherogenic index and VLDL fraction 
The calculated VLDL fraction of lipid profile was lessen in Spirulina platensis treated 
group subsequently the atherogenic potential also reduced significantly (p<0.01) 
compared to isoproterenol control. The atherogenic index was calculated from the 
following formula, 
    Cholesterol – HDL Cholesterol 
Atherogenic Index [14] = 
    HDL Cholesterol 
Table 3 Effect of Spirulina platensis pretreatment (450mg/kg, p.o.) on atherogenic index 
and VLDL fraction. 
Groups Experimental Groups Atherogenic index 
VLDL fraction 
(mg/dl) 
I Control  4.2±0.57 13.1±0.58 
II Isoproterenol control (200 mg/kg s.c.)  7.4±0.99 22.8±0.68 
III S. platensis (450 mg/kg) 3.8±0.30 a 12.2±0.57 b 
IV S. platensis (450 mg/kg) + isoproterenol (200 mg/kg s.c.)  4.2±0.37
 a 16.4±0.63 b 
Values are expressed as mean ± S.E.M. from 6 animals. Statistical analysis by one-way 
ANOVA followed by Tukey’s test using Graphpad Prism software; aP < 0.01 and 
bP<0.05 compared to isoproterenol control (200 mg/kg, s.c.). 
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Discussion 
 
The levels of lipid profile and atherosclerosis risk is reduced in animals pretreated with 
Spirulina platensis for 21 days are presented in table 1, 2 and 3. Spirulina Platensis 
pretreatment and subsequent exposure to isoproterenol results in minimum alteration of 
cholesterol, triglycerides, Low and high-density lipoprotein. 
 
In isoproterenol administered rat group II, cholesterol and triglycerides, LDL and VLDL 
fractions increased significantly with a decrease in HDL cholesterol. In groups IV rats 
(Spirulina platensis + isoproterenol treated) the alterations in the levels of cholesterol and 
triglycerides, LDL, HDL and VLDL fractions were minimum. HDL alters the balance of 
unesterified cholesterol between plasma and cells by increasing its utilization in lecithin 
cholesterol acyl transferase system to form cholesterol ester, which moves rapidly back 
into cells [15]. 
 
The twice isoproterenol (200 mg/kg s.c.) administration results in significant increase in 
serum cholesterol, triglycerides, total lipids and LDL cholesterol. Increased levels of 
circulating cholesterol fractions and its accumulation in heart tissue are well associated 
with cardiovascular damage [8]. Hypertriglyceridemia was seen in isoproterenol-treated 
rats, condition observed in ischemic heart disease, and is due to a decrease in the activity 
of lipoprotein lipase in the myocardium resulting in decreased uptake of triglycerides 
from circulation [9]. The administration of isoproterenol mainly raised LDL cholesterol 
and decreased HDL cholesterol level in serum [16]. 
 
Spirulina platensis affect on lipoprotein lipase activity and hepatic triglyceride lipase 
activities in post-heparin plasma were studied in fructose-induced hyperlipidemic rats 
[17]. The presence of novel protein C-phycocyanin (C-PC) present in Spirulina platensis 
may involve in the inhibition of both jejunal cholesterol absorption and ileal bile acid 
reabsorption [18]. It is found that the aqueous extract of Spirulina platensis may inhibit 
the intestinal absorption of dietary fat by inhibiting pancreatic lipase activity [19]. C-PC, 
one of the major phycobiliproteins of Spirulina platensis (a blue-green alga), which is 
involved in first increased cyclic GMP/VASP Ser157 phosphorylation and subsequently 
inhibits protein kinase C activity, resulting in inhibition of both P47 phosphorylation and 
intracellular Ca2+ mobilization, and secondly may inhibit free radicals (such as hydroxyl 
radicals) released from activated platelets, which ultimately inhibits platelet aggregation. 
This maintains blood homeostasis in experimental animals [20].  
 
The multicomponent spray dried powder of marine algae, Spirulina platensis contains 
substantial amount of gamma-linolenic acid (GLA) may prevent accumulation of 
cholesterol and is also established clinically [21]. One of the earlier studies on the 
reduction of serum cholesterol by Spirulina was that done on rats by Devi and 
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Venkataraman. Since then several workers have confirmed antihyperlipidemic studies 
involving animals and humans [22]. 
 
Spirulina platensis has been proved beneficial in treatments like hepatoprotective effect 
in anti-tubercular drug induced hepatotoxicity in rats [23]. The effect of Spirulina 
platensis powder was successfully evaluated for cholesterol-induced 
hypercholesterolemia by Japanese scientist in rats [24]. The spray-dried powder 
contributes to the treatment in hyperlipidemic condition and in combination of many 
important medicinal plants it can be recommended for the wide use. 
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